Evidence Brief September 11, 2026

This week’s strongest evidence raises a common question across patient-reported outcomes, treatment preferences, health economics, and payer strategy: how much of an observed result reflects the underlying clinical state, and how much depends on the context in which that result is measured?

Peer-Reviewed Evidence

1. McCarvell et al. Response Shift in Oncology: Fact or Myth. Supportive Care in Cancer.

This review examines response shift in oncology: the possibility that patients may recalibrate their internal standards, reprioritize what matters, or reconceptualize quality of life as they adapt to illness and treatment.

These changes can complicate interpretation of longitudinal patient-reported outcomes. Stable or improving quality-of-life scores may reflect genuine improvement, adaptation to illness, or changes in the standards patients use to evaluate their health.

Why it matters

Longitudinal quality-of-life measurements are often treated as though the underlying valuation system remains constant over time.

In oncology, that assumption may not always hold.

Response shift has implications for the interpretation of patient-reported outcomes, health-state utilities, and ultimately QALYs when repeated measurements are used in economic evaluation.

The same issue also matters for preference research. Changes in stated treatment preferences over time should not automatically be interpreted as unreliability. They may represent legitimate adaptation as disease experience, expectations, and priorities evolve.

2. Fabi et al. Patients’ and Oncologists’ Perspectives on Shared Decision-Making and Treatment Communication in HR+/HER2− Advanced Breast Cancer: A Multicountry Survey. BMC Cancer.

This multicountry study examined patient and oncologist perspectives on treatment decisions in advanced breast cancer.

Most patients wanted some degree of involvement in treatment decisions, yet many reported limited knowledge of targeted therapies. Patients and physicians both prioritized survival-related outcomes, while patients placed additional importance on treatment-related adverse effects. Oral treatment was preferred by both groups, although the reasons underlying that preference differed.

Why it matters

Preference elicitation does not occur independently of information.

Patients may strongly value participation in treatment decisions while having incomplete knowledge of the available therapies, expected outcomes, or relevant trade-offs.

For DCEs and other preference studies intended to inform regulatory, payer, or clinical decisions, this raises an important design question:

Are investigators measuring existing preferences, or informed preferences after structured education?

Those are not necessarily the same construct.

Information provision, framing, and respondent understanding should therefore be treated as substantive components of preference-study design rather than simply survey administration details.

3. Zhang et al. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. PharmacoEconomics – Open.

Rather than assuming a fixed drug price and asking whether treatment was cost-effective, the investigators estimated the maximum price at which belantamab plus bortezomib and dexamethasone would meet the relevant willingness-to-pay threshold compared with daratumumab-based therapy.

The resulting value-based price was substantially below the referenced US list price. Alternative survival-extrapolation assumptions changed the precise estimate but did not materially alter the overall conclusion.

Why it matters

Threshold-price analysis can be more decision-relevant than a conventional binary conclusion that a treatment is or is not cost-effective at its current price.

When acquisition price is negotiable, the model can instead answer:

What price would make this intervention represent acceptable value?

That reframes economic evaluation from a retrospective judgment into a potentially actionable tool for pricing and reimbursement negotiation.

The approach may be particularly useful in markets where national reimbursement decisions and negotiated prices are closely linked.

Payer / Policy Watch

ICER will develop a darolutamide value assessment for the Medicare Drug Price Negotiation Program.

The Institute for Clinical and Economic Review announced plans to develop a prostate-cancer value assessment of darolutamide for submission to the Centers for Medicare & Medicaid Services as part of the public-comment process associated with future Medicare drug-price negotiation.

Why it matters

This development further connects formal comparative-effectiveness and health-economic evaluation with US federal drug-price negotiation.

For evidence-generation teams, payer strategy increasingly begins well before reimbursement submission.

Comparator selection, subgroup evidence, long-term effectiveness, treatment sequencing, and economic value may all influence a product’s position years after regulatory approval.

Evidence planning therefore needs to anticipate not only the initial launch decision, but also the possibility that the same evidence base may later be scrutinized in a very different pricing and negotiation environment.

Preprints and Emerging Evidence

No new oncology DCE, DCE-TTO, patient-preference, or health-economic preprint published this week met our threshold for inclusion.

The Evidence Brief favors selectivity over completeness. Preprints are included when they introduce methods or findings with a plausible near-term impact on study design, interpretation, evidence generation, or payer strategy.

What This Means for Evidence Strategy

This week’s evidence illustrates that value is not simply observed. It is conditioned by context.

Patient-reported quality of life may change because the patient's internal standards change. Treatment preferences depend partly on what patients understand when those preferences are elicited. Economic value depends on price, and in a negotiation setting price may be more useful as an output of the analysis than as a fixed model input.

The broader methodological implication is straightforward:

Before interpreting a quantitative result, identify which elements of the decision environment were treated as fixed and which were allowed to change.

Failure to distinguish the underlying clinical outcome from the context in which it is measured can produce apparent precision without equivalent decision certainty.

Worth Reading First

For outcomes and preference methodology, McCarvell et al. is the most consequential paper this week. Response shift raises a fundamental challenge for interpreting longitudinal quality-of-life and utility data in oncology.

For payer strategy, Zhang et al. provides the most immediately actionable methodological idea. Threshold-price analysis moves the question from whether a treatment is worth its current price to the more useful question of what price the available evidence can support.

The ICER/Medicare development is the strategic item to watch. It reinforces an increasingly important reality: evidence generation, health technology assessment, and pricing strategy are becoming progressively more difficult to treat as separate activities.